Retail clinicians should be prepared to field questions about strains of so-called “super lice†that have spread throughout 25 US states thus far.
Retail clinicians should be prepared to field questions about strains of so-called “super lice” that have spread throughout 25 US states thus far.
The US Centers for Disease Control and Prevention (CDC) estimates that head lice infects 6 to 12 million children primarily between the ages 3 and 11 each year.
Usually, parents can simply use OTC treatments and combs to kill and remove the lice within 1 day if used as directed. Currently, however, some strains of circulating lice have built a resistance to pyrethoid, the main pharmacologic agent in OTC lice treatments, so prescription treatment is needed to eradicate these “super lice.”
Parents who are unable to kill their children’s lice with OTC remedies may turn to a retail clinic for counseling on what to do next. Retail clinicians are well positioned to ensure that parents are aware of existing treatment options.
Permethrinis an alternative OTC lotion that doesn’t contain pyrethoid. Patients with lice using permethrin should wash their hair as normal with a shampoo that doesn’t contain conditioners, and then dry the hair, apply the lotion, and leave the product in for 10 minutes before rinsing.
Clinicians should recommend that parents try OTC remedies first because not every child with lice needs to receive prescription treatment. Unnecessary use of the prescription formulation could contribute to future resistance.
If parents’ efforts are fruitless and their child appears to have “super lice,” prescription treatmentsrecommendedby the American Academy of Pediatrics include malathion 0.5%, benzyl alcohol 5%, spinosad 0.9% suspension, and ivermectin 0.5% lotion. Parents should also take supplemental nonpharmacologic measures to prevent reinfestation.
According to the CDC, these measures include the following:
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive Candidiasis
March 27th 2023Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.